Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat ...

Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...

CEO-to-be Maziar Mike Doustdar will need to stem the company’s tumbling share price as market pressures intensify.

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, ...

(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

Preclinical study shows oral PL7737 agonist outperforms tirzepatide alone in rodent models, supporting Palatin’s plans for clinical trials targeting both general and rare forms of obesity.

Pennington Biomedical researchers and their collaborators observed decreased activity in the brain regions responsible for hunger and reward in patients treated with tirzepatide. A recent study has ...

Researchers conducted a post hoc analysis of the SURMOUNT-1 trial to assess the effect of tirzepatide on kidney function in prediabetes with obesity or overweight.

Patients regain weight after stopping weight loss drugs, long-term success may depend on lifestyle and drug choice.